GLM101 for Congenital Disorders of Glycosylation

No longer recruiting at 6 trial locations

Overseen By Study Director Chief Medical Officer, Glycomine, Inc.

Age: Any Age

Sex: Any

Trial Phase: Phase 2

Sponsor: Glycomine, Inc.

Must not be taking: Antibiotics, Antivirals, Antifungals, Steroids

Disqualifiers: Other CDG, Active infection, COVID-19, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 24 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the safety and effectiveness of a new treatment called GLM101 (mannose-1-phosphate replacement therapy) for individuals with a specific genetic condition known as PMM2-CDG. Participants receive weekly infusions of GLM101 at different doses to observe the body's response. The study accepts individuals with a confirmed diagnosis of PMM2-CDG, which can cause various symptoms affecting daily activities. Those with other types of this genetic condition or certain health issues may not qualify. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. However, if you are taking medications for an active infection or systemic steroids, you may need to stop them at least 7 days before screening.

Is there any evidence suggesting that GLM101 is likely to be safe for humans?

Studies have shown that GLM101 is generally safe and well-tolerated. Patients with congenital disorders of glycosylation (CDG) have received more than 200 doses of GLM101, with no reports of serious side effects. This indicates that, so far, the treatment has not caused any major problems for those who have taken it.

GLM101 is a therapy that replaces certain products in the body to aid people with CDG. Administered through an IV, it goes directly into the bloodstream. The ongoing research appears promising, but discussing any concerns with a healthcare professional is always advisable. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Unlike the standard of care for Congenital Disorders of Glycosylation, which typically focuses on managing symptoms and complications, GLM101 offers a new approach by using a novel mechanism of action. GLM101 is administered through weekly intravenous infusions, which could potentially improve glycosylation processes. This targeted action is what makes researchers hopeful, as it might address the underlying cause of the disorder rather than just alleviating symptoms.

What evidence suggests that GLM101 might be an effective treatment for PMM2-CDG?

Research has shown that GLM101 may help treat PMM2-CDG, a rare genetic disorder. Early results from adult patients with PMM2-CDG showed significant health improvements. GLM101 appears to work by correcting a genetic issue that affects protein function in the body. Studies have also reported positive feedback from patients, indicating symptom improvement. These findings suggest that GLM101 could effectively treat the root causes of PMM2-CDG. ^{5 6 7 8 9}

Who Is on the Research Team?

Horacio Plotkin, MD

Principal Investigator

Glycomine, Inc.

Are You a Good Fit for This Trial?

Adults aged 18-65 with PMM2-CDG, a genetic disorder affecting glycosylation. Participants must have low antithrombin III levels and agree to use contraception. Exclusions include severe allergies to GLM101 components, poor venous access, recent major surgery or substance abuse, active infections requiring strong medications, and other significant health issues as determined by the study leads.

Inclusion Criteria

Your antithrombin III (ATIII) levels are below 80%.

I have been diagnosed with PMM2-CDG through genetic testing.

I agree not to donate sperm during and for 30 days after the study.

Exclusion Criteria

I have not had major surgery in the last 30 days.

Has history or presence, upon clinical evaluation, of any illness that might impact the safety of GLM101 infusion or evaluability of drug effect based on the Principal Investigator's and Medical Monitor's discretion

I am not in another drug study and haven't been in one for the last 30 days or 5 half-lives, except for acetazolamide.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive GLM101 intravenously at doses of 10, 20, or 30 mg/kg weekly for 24 weeks to assess pharmacodynamics, safety, tolerability, and pharmacokinetics

24 weeks

Weekly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• GLM101

Trial Overview

The trial is testing GLM101 at doses of 10 and 20 mg/kg for its effects on adults with PMM2-CDG over a period of six months. It aims to assess how the body processes the drug (pharmacokinetics), its safety, tolerability, and potential effectiveness (pharmacodynamics).

How Is the Trial Designed?

Group I: 30 mg/kg GLM101 Experimental Treatment 1 Intervention

GLM101 IV infusions, given weekly

Group II: 20 mg/kg GLM101 Experimental Treatment 1 Intervention

GLM101 IV infusions, given weekly

Group III: 10 mg/kg GLM101 Experimental Treatment 1 Intervention

GLM101 IV infusions, given weekly

GLM101 is already approved in United States, European Union for the following indications:

Approved in United States as GLM101 for:

• PMM2-CDG (Phosphomannomutase 2-congenital disorder of glycosylation)

Approved in European Union as GLM101 for:

• PMM2-CDG (Phosphomannomutase 2-congenital disorder of glycosylation)

Who Is Running the Clinical Trial?

Glycomine, Inc.

Lead Sponsor

Trials

4

Recruited

250+

Published Research Related to This Trial

In a study of 22 Danish patients with carbohydrate-deficient glycoprotein syndrome type 1A, specific PMM2 mutations were identified, with none being homozygous for the R141H mutation, suggesting that this genotype may be incompatible with life due to its severe impact on enzyme activity.

Functional analysis revealed that while some mutations like F119L retained 25% of normal PMM2 activity, others like R141H, G117R, and T237R showed no activity, indicating that at least one mutation must allow for residual enzyme function for patient survival.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Carbohydrate-deficient glycoprotein syndrome type 1A: expression and characterisation of wild type and mutant PMM2 in E. coli. Kjaergaard, S., Skovby, F., Schwartz, M.[2010]

Mannose phosphate isomerase-congenital disorder of glycosylation (MPI-CDG) is linked to a deficiency that leads to serious health issues like hyperinsulinaemic hypoglycaemia and gastrointestinal problems.

A case study of an adult female who stopped mannose supplementation in her adolescence highlights the potential long-term complications of the disorder, including chronic anemia and joint issues, emphasizing the importance of ongoing treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical outcomes in an adult patient with mannose phosphate isomerase-congenital disorder of glycosylation who discontinued mannose therapy. Noman, K., Hendriksz, CJ., Radcliffe, G., et al.[2020]

Mannose supplementation, while intended to correct glycosylation issues in mice with a congenital disorder of glycosylation (CDG), led to significant adverse effects, including reduced litter size and increased embryonic lethality when given to pregnant mice.

The study found that mannose caused specific eye defects in surviving offspring, indicating that altering mannose metabolism during embryonic development can lead to unexpected health issues, suggesting caution for pregnant women considering mannose supplements for potential benefits in fetuses with CDG.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice. Sharma, V., Nayak, J., DeRossi, C., et al.[2021]

Inhibiting the enzyme phosphomannose isomerase (MPI) with the compound MLS0315771 can increase the availability of mannose 6-phosphate (Man-6-P) for glycosylation, which may benefit patients with CDG-Ia, a genetic disorder caused by PMM2 deficiency.

Daily mannose supplementation is effective for CDG-Ib patients but not for CDG-Ia patients, highlighting the potential of MPI inhibitors like MLS0315771 to improve glycosylation in CDG-Ia by redirecting Man-6-P metabolism.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts. Sharma, V., Ichikawa, M., He, P., et al.[2021]

Phosphomannomutase (PMM2) deficiency is a common glycosylation disorder with no current therapy, affecting the N-glycosylation pathway in hundreds of patients.

Potential therapeutic strategies include using small molecules to boost Mannose-1-P levels and enhancing or replacing phosphomannomutase, with further research needed in cell and animal models to evaluate their effectiveness.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients. Freeze, HH.[2021]

The authors argue that dietary mannose supplementation should not be dismissed as a treatment for PMM2-CDG, a genetic disorder affecting glycosylation, and that further investigation is necessary.

They emphasize the importance of conducting controlled prospective clinical trials to evaluate the efficacy of mannose alongside other treatment options for PMM2-CDG.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mannose supplementation in PMM2-CDG. Taday, R., Park, JH., Grüneberg, M., et al.[2021]

Two synthesized compounds, C-I and C-II, were able to normalize the size of lipid-linked oligosaccharides (LLO) and improve glycosylation in fibroblasts from patients with Type I congenital disorders of glycosylation (CDG-Ia), with C-II being about twice as effective as C-I.

C-II not only replenished the GDP-Man pool in CDG-Ia cells but also restored glycosylation levels of a specific protein (DNaseI) to normal levels, demonstrating its potential as a therapeutic option for CDG-I patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblasts. Eklund, EA., Merbouh, N., Ichikawa, M., et al.[2010]

Exogenous mannose supplementation did not increase intracellular levels of mannose-6-phosphate (Man-6-P) in human fibroblasts, including those from patients with Congenital Disorders of Glycosylation (CDG), suggesting it may not negatively affect glycosylation in these patients.

In mouse fibroblasts lacking the enzyme phosphomannose isomerase, increased Man-6-P levels from mannose did lead to a decrease in lipid-linked oligosaccharide (LLO) precursors, but this did not result in reduced overall protein N-glycosylation, indicating that mannose supplementation is unlikely to impair glycosylation in CDG patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Exogenous mannose does not raise steady state mannose-6-phosphate pools of normal or N-glycosylation-deficient human fibroblasts. Higashidani, A., Bode, L., Nishikawa, A., et al.[2021]

Citations

1.

glycomine.com

glycomine.com/glycomine-announces-encouraging-efficacy-data-from-ongoing-phase-2-clinical-study-in-pmm2-cdg/

Glycomine Announces Encouraging Efficacy Data from ...

Initial data from adult patients with PMM2-CDG showed promising evidence of clinical benefit with GLM101 · Notable improvements were seen in ...

2.

glycomine.com

glycomine.com/glycomine-initiates-dosing-in-a-global-randomized-placebo-controlled-phase-2b-study-of-glm101-for-the-treatment-of-pmm2-cdg/

Glycomine Initiates Dosing in a Global, Randomized ...

This randomized placebo-controlled multi-center clinical trial is designed to assess the safety and efficacy of GLM101, an investigational ...

3.

sciencedirect.com

sciencedirect.com/science/article/abs/pii/S1096719224003718

Liposome-encapsulated mannose-1-phosphate therapy ...

Our findings suggest that treatment with GLM101 overcomes the genetic block in the glycosylation pathway and can be used as a potential therapy for CDG.

4.

withpower.com

withpower.com/trial/phase-2-pmm2-cdg-10-2022-7be61

GLM101 for Congenital Disorders of Glycosylation

This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential pharmacodynamic (PD) activity, safety, tolerability, ...

5.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9618201/

Patient reported outcomes for phosphomannomutase 2 ...

Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation ... GLM101, a Potential Treatment for PMM2-CDG ...

6.

glycomine.com

glycomine.com/glm101/

GLM101: A Potential PMM2-CDG Treatment in Clinical Trials

Glycomine has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for GLM101 for the treatment of PMM2- ...

7.

chiesiventures.com

chiesiventures.com/glycomine-announces-encouraging-efficacy-data-from-ongoing-phase-2-clinical-study-in-pmm2-cdg/

Glycomine Announces Encouraging Efficacy Data from ...

Over 200 doses of GLM101 have been administered to patients with PMM2-CDG. The drug appears to be safe and well tolerated with no serious adverse events and ...

8.

sciencedirect.com

sciencedirect.com/science/article/pii/S1096719224004517

Treatment of congenital disorders of glycosylation

Product replacement therapy with mannose-1-phosphate (M1P) in liposomes has been launched as GLM101 by Glycomine. According to available information, GLM101 ...

9.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06892288

NCT06892288 | A Study to Assess the Efficacy and Safety ...

This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, ...